Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Joey Med vs Spry

Joey Med
Graded #460

Lower grade

vs+2.8999999999999986
Spry
Graded #408

Higher grade

The verdict

Spry takes it — 56.8/100 to 53.9/100.

Spry grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Spry is a weight-loss and anti-aging telehealth platform pairing compounded semaglutide ($199/mo) and tirzepatide ($299/mo) with three longevity peptides — BPC-157, NAD+, and sermorelin ($249–$299/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueSpry +9
45
54
Dose & formulationEven
64
64
Clinical oversightSpry +3
52
55
Labs & monitoringSpry +1
51
52
FulfillmentJoey Med +1
62
61
Contract termsEven
55
55
Joey Med · left barSpry · right bar

The numbers

MetricJoey MedSpry
WeighScore53.9/10056.8/100
GradeCC
Scorecard rank#460#408
Semaglutide$279/mo (compounded)$199/mo (starting dose, compounded)
Tirzepatide$399/mo (compounded)$299/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Joey Med

Graded #460 · C

Strengths

  • Three GLP-1 tiers listed with dual pricing on the products page
  • Ships to all 50 states
  • Refund and cancellation policy publicly linked
  • Tampa, FL location anchor provides a geographic identifier
  • Lets patients consolidate weight loss with ED, hair, and longevity treatments

Where it loses points

  • Drug names (semaglutide vs tirzepatide) not disclosed — products sold as 'GLP-1 Core / Plus / High Dose'
  • Compounded vs brand-name not stated (appears compounded but unconfirmed)
  • 503A vs 503B designation not specified
  • Pharmacy partner not named
  • No LegitScript certification mentioned
Spry

Graded #408 · C

Strengths

  • Three named co-founders disclosed (Gabriel Mullins, Sara Yoder, Tyler Bowman) — better-than-average transparency
  • Pricing shown on the homepage ($199 semaglutide / $299 tirzepatide / $249–$299 peptides) — no full sign-up wall
  • Broader range (2 GLP-1s plus 3 anti-aging peptides) appeals to longevity buyers
  • No contracts or commitment required
  • LegitScript Certified with a public verification link

Where it loses points

  • Displays an "FDA Approved" badge though compounded GLP-1s are not FDA-approved finished drugs — potentially misleading
  • Intake reviewed by a nurse practitioner, not an MD
  • States served not disclosed publicly
  • Pharmacy partner not named, and 503A vs 503B designation not specified
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard